The Manufacturers Life Insurance Company Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

The Manufacturers Life Insurance Company purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 9,102 shares of the company’s stock, valued at approximately $236,000.

Other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $112,000. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $265,000. Point72 DIFC Ltd acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $334,000. Virtu Financial LLC acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $390,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $630,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They set an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Oppenheimer initiated coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They set an “outperform” rating and a $48.00 target price on the stock. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Robert W. Baird began coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $45.13.

Dianthus Therapeutics Price Performance

DNTH opened at $29.05 on Friday. The business has a fifty day simple moving average of $27.80 and a 200 day simple moving average of $26.10. The company has a market capitalization of $852.59 million, a PE ratio of -4.98 and a beta of 1.85. Dianthus Therapeutics, Inc. has a 1 year low of $6.58 and a 1 year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.